Table 1.
Relationship between clinicopathological parameters of AC and SCC, and HPV integration
| Variable | Valid HPV integration of AC | Valid HPV integration of SCC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | P-value | Negative | Positive | P-value | |||||
| No | % | No | % | No | % | No | % | |||
| Age | 0.115 | 0.522 | ||||||||
| < 40 | 8 | 32.0% | 17 | 68.0% | 1 | 7.7% | 12 | 92.3% | ||
| 40–49 | 2 | 8.3% | 22 | 91.7% | 1 | 3.4% | 28 | 96.6% | ||
| > = 50 | 3 | 17.6% | 14 | 82.4% | 6 | 11.3% | 47 | 88.7% | ||
| Differentiation | 0.144 | 0.026 | ||||||||
| Well | 2 | 9.1% | 20 | 90.9% | 3 | 33.3% | 6 | 66.7% | ||
| Moderately or poorly | 2 | 40% | 3 | 60% | 5 | 5.8% | 81 | 94.2% | ||
| Stage | 1.000 | 0.273 | ||||||||
| CIS or stage 1 | 9 | 20% | 36 | 20% | 6 | 12.8% | 41 | 87.2% | ||
| Stage 2 + | 1 | 80% | 4 | 80% | 2 | 4.8% | 40 | 95.2% | ||
| Type of HPV | 0.881 | 1.000 | ||||||||
| HPV16 | 6 | 16.7% | 30 | 83.3% | 5 | 7.4% | 63 | 92.6% | ||
| HPV18 | 4 | 16.7% | 20 | 83.3% | 0 | 0.0% | 6 | 100% | ||
| Non-HPV16/18 | 1 | 25.0% | 3 | 75.0% | 1 | 5.3% | 18 | 94.7% | ||
| Lymph metastasis | 0.171 | 0.676 | ||||||||
| Positive | 1 | 100% | 0 | 0% | 1 | 4.5% | 21 | 95.5% | ||
| Negative | 5 | 14.7% | 29 | 85.3% | 7 | 9.6% | 66 | 90.4% | ||